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Abstract
Background: Head and neck mucosal melanoma (HNMM) is a rare type of malignant tumor that frequently
exhibits postoperative recurrence and distant metastasis. Many clinicians administer postoperative adjuvant
radiotherapy to improve patient prognosis and enhance quality of life; however, the effects of this treatment
remain controversial. Therefore, in this study, a meta-analysis was performed to evaluate the practical value of
postoperative adjuvant radiotherapy for head and neck mucosal melanoma.
Methods: Articles in the PubMed, MEDLINE, Cochrane Library, Web of Science and EMBASE databases were
systematically retrieved. Analyses were conducted to compare the impact of treatments involving postoperative
radiotherapy with treatments entailing surgery alone on patient overall survival time, local recurrence and distant
metastasis. The hazard ratio (HR) was used to evaluate the time-to-event data employing RevMan version 5.2 and
Stata/SE version 13.0 software according to the principles specified for systematic reviews of interventions in the
Cochrane handbook.
Results: Twelve cohort studies involving 1593 patients satisfied the desired conditions. In comparing surgery alone
with postoperative radiotherapy, there was no significant difference regarding a decrease in the death risk in HNMM
patients (HR, 1.07; 95 % CI, 0.95–1.2; p = 0.903; low heterogeneity, I2 = 0); this was also the case for sinonasal melanoma
after subgroup meta-analysis (HR, 1.04; 95 % CI, 0.8–1.36; p = 0.983; low heterogeneity, I2 = 0 %). A sensitivity analysis
and subgroup meta-analysis showed that disease progression was the main source of the instability in the results.
Surgery combined with postoperative radiotherapy reduced the risk of local recurrence (HR, 0.51; 95 % CI, 0.35–0.76;
p = 0.155) but did not reduce the risk of distant metastasis (HR, 2.26; 95 % CI, 1.01–5.05; p = 0.006).
Conclusions: This study demonstrated that for HNMM patients surgery is recommended if indicated, and
surgery combined with postoperative radiotherapy is also recommended for dramatically improved local
control of the tumor bed. For patients not suitable for surgical treatment, radiotherapy is still advised. To
control distant metastasis and finally lower the risk of death, immunological therapy is another potential
option whose therapeutic effect needs to be proved with more data from clinical trials.
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Background
Head and neck mucosal melanoma (HNMM) is a rare
type of malignant tumor that accounts for 0.8–3.7 %
of melanomas [1–5]. The onset of mucosal melano-
mas is occult; consequently, most patients have late-
stage mucosal melanoma by the time the disease is
diagnosed. This type of malignant tumor can arise in
any mucosal epithelium. The highest incidence is in
the head and neck region, which accounts for 55.4 %
of all mucosal melanomas, followed by the anus and
rectum (23.8 %), the female reproductive tract (18.0 %)
and the urinary tract mucosa (2.8 %) [1]. The prognosis
for HNMM is poor, with a 5-year overall survival (OS) of
20–33 %. In most cases, lymph node and/or distant
metastasis occurs in the early stages of this disease.
The 5-year disease-specific survival (DSS) rate for
HNMM is 32.4 % [6–8], and the average age range
of patients is 55.5–75 years [6–17]. Because of the
rarity and invasiveness of HNMM, few relevant stud-
ies have examined the diagnosis and treatment of
this disease.
At present, there is no uniform staging method for
HNMM, and no consensus has been reached regarding
treatment regimens for this disease. Surgery is an
optional treatment of choice for HNMM. However, the
anatomical locations of HNMM present complications,
and local and/or distant metastasis has often already
occurred when this disease is first diagnosed; therefore,
after comprehensively considering the surgical risk and
postoperative quality of life, complete resection is ex-
tremely difficult to achieve in many cases. Thus, many
recent studies have reported on the use of postopera-
tive adjuvant radiotherapy for better local control.
However, the prognostic effects of surgery combined
with postoperative adjuvant radiotherapy relative to
surgery alone, with respect to improving patient sur-
vival, remain highly controversial. In addition, chemo-
therapy and biological therapy have also been used in
the adjuvant treatment of HNMM; however, specific
therapeutic strategies and their efficacy have not been
clearly established.
In the present study, to obtain an unbiased and
reliable assessment of the value of postoperative adju-
vant radiotherapy for HNMM, a meta-analysis was
performed. It involved all publications that met the
desired criteria, and compared surgery alone with
surgery combined with postoperative radiotherapy. In
addition, the study included a systematic review of
postoperative radiotherapy treatments and postoperative
chemotherapy with or without combined immunobiologi-
cal therapy. Using these approaches, this study sought to
guide the rational development of clinical treatment
strategies to improve the survival and quality of life of
HNMM patients.
Statement of translational relevance
This meta-analysis pertains directly to the evaluation of
treatment efficacy in oncological clinical trials. We eval-
uated the relationship among the overall survival time,
local recurrence and distant metastasis in HNMM trials.
Treatment involving surgery or radiotherapy alone for
HNMM could result in a decrease in the death risk. In
addition, combination therapy consisting of surgery and
radiotherapy could reduce the risk of local recurrence,
but showed little effect regarding a reduction in the risk
of distant metastasis. No previously published studies
have investigated this topic. This 2a level evidence-based
analysis demonstrated the strong treatment effects of
surgery and radiotherapy in relation to HNMM; more
data are needed to elucidate the efficacy of other treat-
ments such as chemotherapy.
Methods
Literature retrieval strategy
The systematic computer search involved PubMed,
MEDLINE, the Cochrane Library, EMBASE and Web of
Science databases (up to December 2014) with the
following search strings: “head and neck mucosal melan-
oma”; “malignant mucosal melanoma”; “sinonasal melan-
oma”; “nasal melanoma”; “radiotherapy and melanoma”;
“chemical therapy and melanoma”; and “biochemical
therapy and melanoma”. The language of publication
was restricted to English and Chinese. Various refer-
enced publications regarding HNMM, including cohort
studies, retrospective clinical studies, reviews and rele-
vant outcome studies, were collected. Supplements in-
volving manual searching for reference lists of all of the
searched results were carried out to identify other stud-
ies that may have been missed. Publications were
screened according to the current study’s inclusion and
exclusion criteria.
Literature inclusion and exclusion criteria
The literature selection process involved the independent
retrieval of publications by two different researchers
(Wei Li and Yalian Yu). Disagreements were resolved
through discussion or by consultation with a third
researcher (Hailong Wang). With respect to the literature
assessment, for relevant publications, the researchers
recorded the authors’ names, addresses and email ad-
dresses as well as the literature sources of the publications
in question. The authors’ most recent published research
was also examined.
Initial screening criteria
The initial screening criteria were as follows. 1) Study
subjects: Patients with a pathological diagnosis of
HNMM confirmed by immunohistochemistry who had
no other type of malignant tumor. 2) Study type: cohort
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studies. 3) Intervention measures: A comparison be-
tween surgery alone and surgery combined with post-
operative radiotherapy; studies involving different
surgical procedures and radiotherapy regimens were
included for consideration. 4) Result assessment in-
cluded the following data: (1) OS, which referred to the
duration of time from diagnosis or the start of treat-
ment to death, the completion of follow-up, or loss to
follow-up; (2) local recurrence (LR), which referred to
the duration of time from diagnosis or the start of
treatment to the LR of the tumor; (3) distant metastasis
(DM), which referred to the duration of time from diag-
nosis or the start of treatment to the discovery of
metastasis in distant organs; and/or (4) adverse reac-
tions related to adjuvant treatment.
Exclusion criteria
Publications were excluded in accordance with the pro-
cedures described by the Cochrane Non-Randomized
Studies Methods Group [18]. The titles and abstracts of
all retrieved publications were carefully reviewed to ex-
clude publications that clearly did not meet the specified
criteria, such as duplicated reports (if reports from dif-
ferent stages of the same study were retrieved, the most
recent report was retained for the analyses carried out in
the present study), case reports, and reports in which
radiotherapy was combined with biological therapy,
chemotherapy and/or other types of adjuvant therapies.
The relevant data extracted from the research litera-
ture that met the specified criteria were as follows. 1)
Literature characteristics (such as the publication’s coun-
try or region, authors, title and publication year; the
name of the journal in which the study was published;
and the authors’ addresses or email addresses). 2) Type
of research (for instance, whether a publication was a
prospective or a retrospective study). 3) Study elements,
including the basic characteristics and disease conditions
of the examined cases (for example, the study period,
basic information for the enrolled patients, inclusion
and exclusion criteria, and duration of follow-up time or
time at which patients were lost to follow-up). 4) Inter-
ventions (for instance, treatment regimens). 5) Final data
that reflected the quality of the research (for example,
OS, LR, DM and side effects).
Assessment of risk of bias regarding the eligible literature
Evaluation criteria: Each publication was independently
evaluated by two researchers (Wei Li and Yalian Yu)
according to the revised Newcastle-Ottawa Scale (NOS),
which was developed to assess non-randomized con-
trolled studies (NRSs) [19]. The between-group compar-
ability of different intervention measures was analyzed
using the NOS. We focused on the following factors that
affected prognosis: follow-up time; age; primary site (the
nasal cavity, a paranasal sinus, the oral cavity, the naso-
pharynx, or the soft palate among other sites); the surgi-
cal approach (endoscopic or open surgery); treatment
with postoperative radiotherapy; radiotherapy regimen (a
conventional radiotherapy regimen, a proton beam ther-
apy [PT] radiation regimen, or a carbon-ion therapy
[CIT] radiation regimen); and the completeness of the
final study data (follow-up time and outcome [recur-
rence, metastasis, survival or death]). The revised evalu-
ation criteria are presented in Table 1.
Data analysis
Meta-analysis method
In this study, a quantitative analysis research method
was employed. Data analysis and processing were
performed using RevMan version 5.2 (The Cochrane
Collaboration, Oxford, UK) and Stata/SE version 13.0)
software according to the principles specified for
Systematic Reviews of Interventions in the Cochrane
Handbook.
Study effect sizes
The hazard ratio (HR) was used to evaluate the time-to-
event data (for example, OS, LR and DM) in treatment
efficacy assessments. For documents that did not provide
HRs, the HR was calculated using the method described
by Tierney et al. [7]. If the HR could not be directly
obtained, then the SPSS 17.0 software package was
employed to obtain a HR and a 95 % confidence interval
(CI) from the raw data (treatment regimen, follow-up
time, and endpoint event) using unvaried Cox propor-
tional regression models. If raw data could not be
obtained by directly contacting the authors of a publica-
tion, the publication in question was excluded from our
analysis.
Tests of heterogeneity
Heterogeneity was analyzed using chi2 tests and I2 test.
The criterion used for this analysis was a = 0.05; that is,
p < 0.05 indicated a statistically significant difference.
Revman software, version 5.2, was also used to examine
heterogeneity using the Peto method. I2 was used to
represent levels of heterogeneity; in particular, an I2
value <25 % indicated low heterogeneity, an I2 value of
25–50 % indicated moderate heterogeneity and an I2
value of ≥50 % indicated high heterogeneity. If study ef-
fect sizes were sufficiently homogeneous, a fixed-effects
model was used; if these effect sizes were heterogeneous,
a random-effects model was applied.
Publication bias and sensitivity analyses
Publication bias was estimated using the funnel plot, and
quantified by means of the Egger test using Stata/SE
version 13.0 software. The heterogeneity may be increased
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Table 1 Criteria for judgment risk of bias for each study




Any criteria descriptions for
the patients




The representativeness of the
postoperative radiotherapy
group
truly representative of the average, elderly,
community-dwelling resident
somewhat or selected group of patients, e.g.
only certain socio-economic groups/areas
no description of the
derivation of the cohort
The representativeness of the
surgery only group
drawn from the same community as the
intervention cohort
drawn from a different source no description of the




age b.negative margin c
patinet status
All the three variables were comparable
between the groups
at least one of these was not reported even





All the three variables were comparable
between the groups
At least one of those was not comparable even
if others were not reported
Not mentioned
Control for confounding at
each outcome
Appropriate methods are used to control
the potential confounders (e.g. matching,
modeling, etc.)
No method was applied to control the potential
confounders
Insufficient description
Design or Analysis bias
Blinding of participants at
each outcome
1.Blinding of participants at each outcome 1. No blinding or incomplete blinding, the
outcome is likely to be influenced by lack
of blinding
Insufficient description
2.No blinding or incomplete blinding, but
the reviewers judge that the outcome is
not likely to be influenced by lack of blinding
2. Blinding of key study participants and likely
that the blinding could been broken, and the
outcome is likely to be influenced by lack
of blinding
3. Blinding of key study participants and unlikely
that the blinding could been broken
Ascertainment of intervention
exposure
Medical records or structured interview Written self report Insufficient description
Outcomes
Blinding of outcome assessment
at each outcome
1. Blinding of outcome assessment at each
outcome
1. No blinding of outcome assessment, the
outcome measurement is likely to be influenced
by lack of blinding.
Insufficient description
2. No blinding of outcome assessment, but
the reviewers judge that the outcome
measurement is not likely to be influenced
by lack of blinding.
2. Blinding of outcome assessment ensured,
and likely that the blinding could have been
broken and the outcome assessment is likely
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3. Blinding of outcome assessment ensured,
and unlikely that the blinding could have
been broken.
Ascertainment of outcome data Record linkage Self report Insufficient description
Was follow up long enough
for outcomes to occur
The follow-up was long enough for
outcomes to occur, if median duration of
follow-up > = 6 month
if median duration of follow-up < 6 months Insufficient description
Adequacy of follow up of
cohorts
1. complete follow up: all subjects accounted
for
follow up rate < 80 % (select an adequate %)
and no description of those lost
Insufficient description
2. subjects lost to follow up unlikely to introduce
bias: number lost < = 20 %, or description
of those lost suggesting no different from
those followed
1. Cochrane Handbook for Systematic Reviews of Interventions http://handbook.cochrane.org/. Accessed 2014 Dec 6










by a number of research methods such as: 1) different
features of the study design in the subgroup analyses of
different studies, as well as the use of different surgical
procedures and/or radiotherapy regimens; and 2) evalu-
ation of potential confounding factors regarding disease
progression.
Sensitivity analyses estimated the stability by means of
the meta-trim method.
Results
Characteristics of the included publications
Eight hundred and thirty-three records were identified
through the literature retrieval strategy initially. After
the first screening based on the abstracts and titles, 801
records were excluded, and 32 full texts records
remained for further reviewed. An additional 20 records
were eventually excluded for 16 of them were mixed
chemical or biotherapy in both group and 4 of them
were confused records. Ultimately, 12 eligible records
were included in this meta analysis. A flow diagram of
the study selection is shown in Fig. 1.
A total of 12 investigations (involving 1593 patients)
that satisfied the requirements for NRS publications
were included in the present study (6, 7, 10–17, 19, 20).
These investigations were all cohort studies, and the full
text of each of the corresponding publications could be
obtained. The relevant information and characteristics of
each included publication are presented in Table 2. Both
reviewers were in agreement regarding the selection of
the 12 studies for the meta-analysis.
Among the included publications, there were five multi-
center studies [6, 7, 11, 14, 15] and seven single-institution
non-multicenter studies [10, 12, 13, 16, 17, 19, 20]. In cases
of HNMM, the primary tumor was located in various
sites of the head and neck mucosa, such as the nasal
cavity, paranasal sinus, nasopharynx, oral cavity or
oropharynx, among other locations [1]. Cases of paranasal
sinus or nasal mucosal melanoma (SNMM) account for
the majority (72.2 %) of HNMM cases and have similar
characteristics to other mucosal melanomas [19]; conse-
quently, publications examining mucosal melanomas of
the nasal cavity and the paranasal sinuses were also
included in this study. Thus, the included publications
consisted of six HNMM studies [6, 11, 14–16, 19] and six
SNMM studies [7, 10, 12, 13, 17, 20]. High intervention
variability among NRSs is inevitable. Moreover, there is no
uniform treatment strategy for HNMM patients. In the
postoperative radiotherapy group, most investigators used
either traditional radiotherapy with conventional radiation
doses [19], low-dose fractionated radiotherapy [10] or
mixed radiotherapy (in which certain patients received
conventional doses and the remaining patients received
low-dose fractionated radiotherapy, but the authors did
not provide additional specifics) [11, 13, 14, 20]; other
publications did not specifically report their radiotherapy
strategies [6, 7, 11, 12, 19]. Descriptive evaluations of the
related bias of the included publications are presented
in Table 3. Eligible data could not be retrieved from
all of the included publications. Therefore, in the final
meta-analysis, 12 publications were used for OS ana-
lysis [6, 7, 10–13, 15–17, 19, 20], five publications
matched the criteria for local control analysis [11, 12,
14, 16, 17] and four publications matched the criteria
for DM analysis [11, 12, 16, 17].
Survival data
There was no significance difference between surgery
alone and postoperative radiotherapy regarding a de-
crease in the death risk; in 11 cohort studies involving
1565 patients, the HR was 1.07, the 95 % CI was 0.95–
1.20 and there was low heterogeneity (I2 = 0). Further-
more, postoperative radiotherapy did not reduce the
Fig. 1 Flow diagram for quantitative studies
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risk of death among SNMM patients (HR, 1.04; 95 %
CI, 0.80–1.36; heterogeneity, p = 0.983, I2 = 0 %) in
fixed-effects models (Fig. 2). However, the subgroup
meta-analyses of the LR demonstrated that postopera-
tive radiotherapy could reduce the risk of local recur-
rence by 45 % in a random-effects model (six cohort
studies involving 382 patients [HR, 0.55; 95 % CI, 0.32–
0.93; heterogeneity, I2 = 38 %; p = 0.15; Fig. 3a). In
addition, the random-effects model for the subgroup
meta-analysis of DM revealed that postoperative radio-
therapy did not reduce the risk of DM (HR, 2.26; 95 % CI,
1.01–5.05; heterogeneity, I2 = 76 %; p = 0.006; Fig. 3b).
Sensitivity analyses estimated stability using the meta-
trim method (Fig. 4a); after evaluating three studies, our
new meta-analysis gave the same result [HR, 1.037; 95 %
CI, 0.927–1.160; p = 0.524). This proved the stability of
the conclusion, namely that postoperative radiotherapy
could reduce the risk of death. Publication bias was
tested using the funnel plot (Fig. 4b). The Egger test
used to quantify the publication bias (p = 0.290) showed
no small-study effects, which confirmed the results did
not reveal an obvious asymmetry.
Discussion
Twelve retrospective studies that examined a total of
1593 patients were included in the current investigation.
All of these studies were descriptive cohort studies, and
they provided moderately strong evidence. Given that
HNMM is rare and is associated with an extremely poor
prognosis, the results of this study can nonetheless
provide significant guidance in making clinical treatment
decisions regarding this disease.
The preferred treatment method: surgical resection
The subjects included in the current study were patients
with a history of past surgical treatment; for mucosal
Table 2 Characteristics of each included publications
Head and neck mucosal melanoma
Trial & year Diagnose year Number Interventions Average age(year)a Follow-up(month)
Jethanamest D(2011) [6] 1973-2007 totle815b Surgery only 68.7(17–100) ungiven
S + R
Benlyazid A(2010) [11] 1980-2008 82 Surgery only 67(30–97) 65.2mon
78 S + R
Owens JM(2003) [16] 1986-1998 20 Surgery only 55.5(3mon-88y) ungiven
24 S + R
Krengli M(2006) [14] 1972-2002 17 Surgery only 66(40–87) 38(1–207)mon
42 S + R
Meleti M(2008) [21] 1976-2006 19 Surgery only 63.7(31–91) 27.8(2–80)mon
19 S + R
Temam S(2005) [15] 1979-1997 30 Surgery only 58(21–90) 45.6(8–384)mon
39 S + R
Sinonasal melanoma
Gal TJ(2011) [7] 2000-2007 128 Surgery only 72.1 ungiven
117 S + R
Thariat J(2011) [10] 1991-2006 13 Surgery only 73 39(1–181)mon
10 S + R
Roth TN(2010) [12] 1992-2007 12 Surgery only 71(40–94) (7–132)mon
13 S + R
Brandwein MS(1997) [17] 1977-1995 17 Surgery only 65(23–83) 59(1–217)mon
8 S + R
Cheng YF(2007) [13] 1982-2002 totle23b Surgery only 68.2(35–87) 3-132mon
S + R
Sun CZ(2014) [20] 1976-2005 18 Surgery only 55(2–79) 6-114mon
13 S + R
S + R:postoperative radiotherapy
aAge at first diagnosis
bstudies that cannot separate the surgery only group from the postoperative radiotherapy group in number
Li et al. BMC Cancer  (2015) 15:758 Page 7 of 16
melanoma surgery achieves better results than other
therapeutic approaches with respect to treatment and
local control. Moreover, surgery was the first treatment
for many patients in the vast majority of examined
publications. In an examination of 815 HNMM patients,
Thomas et al. [6] found that compared with patients
Table 3 Assessment of risk of bias of included cohort studies
Criteria Jethanamest D Benlyazid A Owens JM Krengli M Meleti M Temam S
(2011) [6] (2010) [11] (2003) [16] (2006) [14] (2008) [21] (2005) [15]
Any criteria descriptions for the patients yes yes yes yes yes yes
The representativeness of the surgery only group yes yes yes yes yes yes
The representativeness of the postoperative radiotherapy group yes yes yes yes yes yes
Group comparable for: yes yes yes yes yes yes
a.average age b.negative margin c patinet status
Group comparable for: unclear unclear unclear unclear unclear unclear
a.tumor site b.radiotherapy plan c.tumor stage
Control for confounding at each outcome(OS)a yes yes no unclear no unclear
Control for confounding at each outcome(LR)a unclear yes no yes no unclear
Control for confounding at each outcome(DM)a unclear yes no unclear no unclear
Blinding of participants at each outcome yes yes yes yes yes yes
Ascertainment of intervention exposure yes yes yes yes yes yes
Blinding of outcome assessment at each outcome yes yes yes yes yes yes
Ascertainment of outcome data yes yes yes yes yes yes
Was follow up long enough for outcomes to occur(OS) yes yes yes no yes yes
Was follow up long enough for outcomes to occur(LR) no yes yes yes no yes
Was follow up long enough for outcomes to occur(DM) no yes yes no no yes
Adequacy of follow up of cohorts unclear unclear unclear unclear unclear unclear
Criteria Gal TJ Thariat J Roth TN Brandwein MS Cheng YF Sun CZ
(2011) [7] (2011) [10] (2010) [12] (1997) [17] (2007) [13] (2014) [20]
Any criteria descriptions for the patients yes yes yes yes yes yes
The representativeness of the surgery only group yes yes yes yes yes yes
The representativeness of the postoperative radiotherapy group yes yes yes yes yes yes
Group comparable for: yes yes yes yes yes yes
a.average age b.negative margin c patinet status
Group comparable for: unclear unclear unclear unclear unclear yes
a.tumor site b.radiotherapy plan c.tumor stage
Control for confounding at each outcome(OS)a yes no no no no yes
Control for confounding at each outcome(LR)a unclear no no no no unclear
Control for confounding at each outcome(DM)a unclear no no no no unclear
Blinding of participants at each outcome yes yes yes yes yes yes
Ascertainment of intervention exposure yes yes yes yes yes yes
Blinding of outcome assessment at each outcome yes yes yes yes yes yes
Ascertainment of outcome data yes yes yes yes yes yes
Was follow up long enough for outcomes to occur(OS) yes yes yes yes yes yes
Was follow up long enough for outcomes to occur(LR) no yes yes yes yes no
Was follow up long enough for outcomes to occur(DM) no yes yes yes yes no
Adequacy of follow up of cohorts unclear unclear unclear unclear unclear unclear
OS overall survival time, LR local recurrence, DM distance metastasis
aconfounding factors means other intervening measures that may effect the outcomes(eg. chemical therapy etc.)
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who received surgery alone, the relative risk ratios for
patients who received simple radiotherapy or no treat-
ment were 1.56 (95 % CI, 1.35–1.72) and 2.38 (95 % CI,
2.09–2.59), respectively. The clinical significance of these
findings was that compared with the administration of
surgical treatment, the administration of radiotherapy
alone and the administration of no treatment increased
the risk of death by 56 and 138 %, respectively. Thus,
patients who underwent surgical treatment (with or
without postoperative radiotherapy) had better progno-
ses and longer survival times than patients who did not
receive surgical treatment. In a study by Andersen et al.,
all surviving patients had received surgical treatment;
however, the non-surgical treatment approach involving
chemoradiotherapy alone had little or no therapeutic
effect [5].
Furthermore, the 2012 National Comprehensive Can-
cer Network (NCCN, an American organization) guide-
lines recommend surgery as the preferred treatment for
mucosal melanoma patients; in particular, the optimal
objective for surgical treatment is en bloc resection that
effectively achieves tumor-free margins (NCCN Guide-
lines Version 1.2012, Mucosal Melanoma of the Head
and Neck). However, surgical treatment is only suitable
for patients with stage III–IVA cancer in the American
Joint Committee on Cancer (AJCC) staging system (7th
edition). In these stages, cancer is limited to the mucosal
layer or exhibits moderate progression; that is, the
tumor may have invaded deep soft tissues, cartilage,
bone or surface skin covering the tumor, but there is no
lymph node metastasis or DM [19].
Unfortunately, most HNMM patients are already at an
advanced clinical and pathological stage of the disease
when they are first diagnosed; as a result, their progno-
ses are far worse than the prognoses of cutaneous mel-
anoma patients, for whom surgical treatment is also the
preferred therapeutic approach [21, 22]. When cutane-
ous melanoma patients are first diagnosed, the percent-
age of patients at stages 0, I, II, III, and IV (using AJCC
staging) are 14.9, 47.7, 23.1, 8.9 and 5.3 %, respectively;
many patients undergo surgery or other effective inter-
ventions at the early stages of this disease. A survey of
84,836 melanoma patients indicated that 91.5 % of cuta-
neous melanoma patients underwent surgery, and that the
5-year survival rate for cutaneous melanoma was 80.8 %
[1]. However, for HNMM, because of complexities associ-
ated with the anatomical location of the primary tumor, it
is often difficult to achieve negative safety margins during
the microscopic resection of this tumor [4]. In particular,
it is very difficult to completely resect paranasal sinus
mucosal melanomas that are located near the cribriform
plate or the skull plate, or that have invaded the anterior
skull base [23]. Therefore, many researchers believe that it
is unwise to attempt to achieve complete resection at the
expense of increasing surgical risk and reducing post-
operative quality of life [24, 25]. However, a lack of
complete resection increases postoperative complica-
tions and thereby affects patient prognosis.
Fig. 2 Forest plots of postoperative radiotherapy vs. surgery alone group on the overall survival time in HNMM by the subgroup analysis
for SNMM
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Postoperative radiotherapy is effective for local control,
but does not reduce the risks of DM and death
In the present study, a random-effects model was used
for the meta-analysis of the effects of postoperative
radiotherapy on the local control (assessed in terms of
LR) of HNMM. Relative to surgery alone, surgery com-
bined with postoperative radiotherapy can reduce the
risk of LR by 45 % (five NRSs with a total of 336
patients; HR, 0.55; 95 % CI, 0.32–0.93; p < 0.05). How-
ever, postoperative radiotherapy did not reduce the risk
of postoperative death in HNMM patients (nine NRSs
with a total of 1465 patients; HR, 1.07; 95 % CI, 0.95–
1.02). Postoperative radiotherapy also did not reduce the
risk of death in cases of SNMM (five NRSs with a total
of 341 patients; HR, 1.04; 95 % CI, 0.79–1.36).
Because HNMM is multicentric, the clinical boundar-
ies of this disease are blurred and unclear; infiltration
occurs, particularly submucosal lymphoid infiltration in-
volving melanoma cells [26], resulting in a high rate of
postoperative LR (31–85 %) [27]. Therefore, even if
HNMM is diagnosed early and aggressive surgical treat-
ment is administered, postoperative adjuvant treatment
remains necessary. Among the possible adjuvant treat-
ments, postoperative radiotherapy is one of the earli-
est examined adjuvant therapies; it has been used in a
relatively large number of clinical cases. The purpose
of radiotherapy is to reduce the postoperative invasion of
residual tumors into the surrounding normal tissues. The
NCCN has noted that postoperative radiotherapy is suit-
able in cases with extra capsular lesions, the invasion of
two or more neck or parotid gland lymph nodes, a single
nodule ≥3 cm and neck dissection without distant
invasion or postoperative LR. The use of conventional
radiotherapy doses (2 Gy per fraction, at a total dose
of 60–66 Gy or 70 Gy) is recommended. In addition,
secondary damage from radiotherapy is regarded as
acceptable. The current study confirmed that although the
adjuvant treatment approach outlined above produced
Fig. 3 a Forest plots of postoperative radiotherapy vs. surgery alone group on the LR for HNMM; (b) Forest plots of postoperative radiotherapy
vs. surgery alone group on the DM for HNMM
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good local control effects, it did not reduce the risk
of death. The reasons for this phenomenon are ana-
lyzed below.
First, HNMM is a radiotherapy-resistant tumor; that
is, HNMM tumors exhibit extremely strong sublethal
damage repair capacities. Therefore, although conven-
tional radiotherapy doses can achieve local control,
traditional radiotherapy is ineffective in controlling
the disease as a whole. For this reason, stereotactic
intensity-modulated radiation therapy (IMRT), PT and
CIT have recently been developed for the adjuvant
treatment of HNMM. Although these novel approaches
have exhibited enhanced efficacy relative to conventional
radiotherapy, they remain at the clinical trial stage; thus,
numerous clinical trials and prospective studies will be
required to determine the long-term efficacy of these
treatments.
Second, mucosal melanoma is a systemic disease that
readily invades vascular and lymphoid tissues and there-
fore characteristically tends to produce DM. Thus, it is
difficult for local radiotherapy to achieve good control of
the hematogenous metastasis of this disease [24]. Not-
ably, many mucosal melanoma patients die from the
spread of the disease rather than from LR. Rinaldo
et al. [27] have demonstrated that in contrast to
primary squamous cell carcinoma of the nasal cavity
and the paranasal sinuses, which mainly exhibits pos-
terior pharyngeal wall and mandibular lymph node
metastasis, mucosal melanoma more frequently exhibits
lung and brain metastasis [28]. Consequently, although
Fig. 4 a Funnel plot analysis of Sensitivity analyses for included studies; (b) Funnel plot analysis of publication bias for included studies
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postoperative adjuvant radiotherapy has relatively
strong local control effects, it is not a protective factor
for HNMM because the main cause of death in certain
HNMM patients is DM.
Finally, because of the rarity of HNMM, it is extremely
difficult to conduct large-sample RCTs for the examin-
ation of this disease. Therefore, selection bias in the
meta-analysis of cohort studies will have caused uncer-
tainty in the results of the present study. In other words,
in the included retrospective studies, most patients who
received postoperative radiotherapy were late-stage cases
involving failed en bloc resection, positive safety mar-
gins, lymphatic vascular invasion and/or DM. However,
it was determined that for these patients, postoperative
radiotherapy could still achieve local control but did not
reduce the risk of death.
Value of other treatment methods in non-surgical therapy
As discussed above, surgical treatment is difficult to
implement in HNMM cases because of various issues
including: complications associated with the anatomical
location of a tumor (particularly in the case of SNMMs
located near important organs); the advanced stage of
the disease upon initial diagnosis; patient refusal of
surgical treatment; and the comprehensive consideration
of surgical risk and postoperative quality of life. Conse-
quently, to increase survival rates and prolong patient
survival times in HNMM cases, many researchers
advocate the use of radiotherapy, chemotherapy and/
or biological therapy alone as alternatives to surgical
treatment.
Evaluation of the therapeutic efficacy of simple
radiotherapy for HNMM
In recent years, with the continuous advancement of
radiotherapy techniques and the upgrading of relevant
equipment, clinicians have gradually begun to increase
the use of radiotherapy alone in the treatment of
primary HNMM. Although the development of specific
therapeutic strategies remains controversial, studies have
already proven the efficacy of this approach and have
demonstrated that the side effects of the radiotherapy
are within manageable ranges.
Douglas et al. [29] recommended radiotherapy as the
preferred treatment approach for HNMM patients who
cannot withstand surgery or refuse surgical treatment. In
a retrospective study of 68 HNMM patients, 13 patients
received palliative radiotherapy, 30 received radiotherapy
at therapeutic doses and 25 received surgical treatment
with or without postoperative radiotherapy. Radical
treatment mainly using radiotherapy achieved relatively
good local control effects and a 5-year DSS of 25 %.
However, there have been few relevant reports on the
use of radiotherapy at therapeutic doses, and these
reports have involved small sample sizes. These limita-
tions occurred because HNMM is a radiotherapy-
resistant tumor with extremely effective sublethal repair
capabilities. Therefore, therapeutic hypofractionated
radiotherapy (HF-RT) with an α/β ratio of 4–6 Gy per
fraction has been used to overcome this radiotherapy
resistance. The basic dose for the treatment of uveal
melanomas is 1.5–26.2 Gy, with an average of 10 Gy,
and the basic dose for cutaneous melanomas is 1.6–
6 Gy, with an average of 2.5 Gy; however, the dose for
mucosal melanoma remains unknown [30]. Wada et al.
[31] performed high-dose HF-RT with doses ≥3 Gy in
31 HNMM patients. They found that compared with
conventional postoperative radiotherapy, HF-RT deliv-
ered better local control and survival; in particular, HF-
RT resulted in 1- and 3-year DSS rates of 73 and 33 %,
respectively. Moreover, increased radiotherapy doses
produced better therapeutic effects with respect to local
control and survival. However, with the aforementioned
radiotherapy regimen, the occasional occurrence of le-
thal side effects, such as mucosal ulceration and massive
hemorrhage, is inevitable. Christopherson et al. [32]
administered therapeutic doses of radiotherapy or post-
operative radiotherapy to 21 patients. They found that
three patients (17 %) experienced serious complications,
including the need for hospitalization and/or surgical
intervention, failing to complete the entire radiotherapy
regimen, and death. Two of these patients received PT
alone, and one patient received photon therapy and PT.
The manifestations of the complications included bilat-
eral blindness, severe mucositis and skin necrosis. Thus,
numerous clinical studies involving HF-RT are still
required to develop regimens with optimal therapeutic
effects and ensure that the side effects of these regimens
are manageable.
Given the side effects of HF-RT, local dose-escalated
IMRT, another improved photon radiotherapy tech-
nique, has been used in clinical practice. In a study on
the treatment of malignant tumors of the paranasal
sinuses, Madani et al. [33] reported that IMRT was the
gold standard for radiotherapy approaches for these
tumors, and that IMRT could be used alone or as an
adjuvant treatment. Combs et al. [34] used IMRT to
treat eight SNMM patients and found a 5-year OS of
80 %, a 3-year local progression-free survival rate of
28.6 % and a 3-year distant progression-free survival
rate of 28.6 %. In addition, during the 27 months (12–
71 months) of follow-up, radiotherapy-related side ef-
fects were within acceptable ranges. No vision loss or
blindness occurred, and additional therapeutic inter-
vention was not required. However, both the afore-
mentioned HF-RT approach and this IMRT approach
produced non-ideal effects with respect to the control
of DM.
Li et al. BMC Cancer  (2015) 15:758 Page 12 of 16
At present, PT and CIT particle therapies achieve
better local control of melanomas than surgery alone,
conventional photon radiotherapy, or a combination of
surgery and photon radiotherapy. Therefore, the use of
PT or CIT particle radiotherapy alone for HNMM is
attracting widespread attention. Because PT and CIT can
provide precisely distributed radiation doses, these tech-
niques can be used to specifically deliver high doses of
radiation to tumors with a reduced risk of radiation
exposure to normal tissues; this characteristic is particu-
larly relevant for malignant tumors located in or near
important tissues and organs [28, 35]. In contrast to the
high levels of attenuation characteristic of the traditional
photon beams used for radiotherapy upon penetrating
soft tissues, proton beams exhibit tremendous energy
deposition in targeted tumors but minimal energy de-
position in the preceding or subsequent normal tissues;
consequently, proton beams can be used to accurately
deliver radiation to tumors with relatively little effect on
the surrounding normal tissues [36, 37]. This characteris-
tic is highly suitable for the treatment of paranasal sinus
melanomas because the radiotherapy dose required for
the treatment of these tumors is extremely similar to the
doses that affect the surrounding normal tissues, such as
the eyes, the optic nerves, brain tissues and the skull.
Compared with photon beam radiotherapy, PT is associ-
ated with lower risks regarding the development of sec-
ondary malignant tumors [33, 34]. In an examination of
11 cases treated with PT, the initial disease control rate
was 85.7 %, the 3-year survival rate was 58.0 % and the
mean disease-free time to progression was 25.1 months
(with a mean follow-up time of 36.7 months); there were
two cases of unilateral vision loss but no blindness events
[38]. In addition, in 72 cases treated using CIT, the 5-year
local control rate for the disease was 84.1 %; 94.4 % of the
patients who exhibited good local control received radio-
therapy with ≥3.6 Gy/fraction. However, by the end of the
follow-up, DM had occurred in 40 cases; LR had not oc-
curred in 34 of these cases (85.0 %). These results con-
firmed that the tumors had often already invaded their
microenvironment before treatment had begun and that
the examined radiotherapy approach did not produce
good control of HNMM that underwent early-stage
hematogenous DM [39]. In contrast, compared with pro-
ton beams, carbon-ion beams have a better penumbra and
higher relative biological effectiveness. However, Demizu
et al. [40] demonstrated that PT and CIT did not exhibit
significant differences regarding therapeutic effectiveness
in the treatment of HNMM; in particular, the 2-year
survival rates among patients treated with PT and CIT
were 58 and 62 %, respectively (p = 0.399; Kaplan-
Meier [K-M] curve analysis). PT and CIT also had no
significant differences regarding local control effects;
these treatments resulted in local control rates of 83
and 59 %, respectively (p = 0.569; K-M curve analysis).
In addition, the radiotherapy side effects of PT and
CIT did not differ significantly. Although CIT and PT
particle therapies had excellent local control effects (with
an effective 2-year local control rate of 78 %), their out-
comes regarding OS were not ideal (a 2-year DSS of 31 %).
The analysis appeared to indicate that this phenomenon
could be attributed to a relatively high incidence of
DM. Thus, although the toxic side effects of radio-
therapy could be controlled to within tolerable levels,
the effects of particle radiotherapy with respect to
controlling DM were not ideal.
In summary, the value of radiotherapy in the treat-
ment of HNMM should receive extensive attention in
future studies. With the advancement of radiotherapy
techniques and constant upgrading of the relevant
equipment, solutions that address the issue of radiother-
apy side effects may be developed in the near future.
Numerous controlled clinical studies and prospective
studies are still required to establish radiotherapy regi-
mens that achieve therapeutic objectives, but produce
manageable side effects. In addition, because mucosal
melanoma is a systemic disease, therapeutic approaches
that combine radiotherapy with chemotherapy or immu-
nobiological therapy can be designed to compensate for
the deficiencies of radiotherapy alone, with respect to
controlling the high incidence of DM in cases of muco-
sal melanoma.
Immunobiological therapy
Compared with cutaneous melanoma, mucosal melan-
oma involves more chromosomal abnormalities and ab-
normal gene copies [41]. At present, gene therapies
targeting the mutation hotspots of malignant melanoma
have already entered clinical trials. In particular, a phase
III clinical trial has confirmed that vemurafenib, a select-
ive BRAF inhibitor, produces a higher response rate
(48 % vs 5 %) and 6-month OS (84 % vs 64 %) compared
with decarbonizes, another systemic chemotherapeutic
agent [42]. In a phase II clinical trial, imatinib, a targeted
therapeutic agent for melanomas designed to be effective
in cases involving KIT mutations, exhibited outstanding
performance; it achieved a significantly higher response
rate in melanomas with KIT mutations than in wild-type
melanomas (40 % vs 0 %; p = 0.005) [43]. A recent phase
II clinical trial confirmed that patients with NRAS
(neuroblastoma RAS viral [v-ras] oncogene homolog)
mutations could benefit from treatment with MEK1/2
inhibitors (MAP/ERK kinases 1 and 2) [44]. The muta-
tion rates of KIT, NRAS, and BRAF mutations among
SNMM patients were 7.91 % (11/139), 12.9 % (18/139)
and 2.16 % (3/139), respectively [43, 45–48]. Analysis of
the above data revealed that there are relatively low rates
of KIT and BRAF mutations among SNMM patients.
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Consequently, few SNMM patients will benefit from
chemotherapeutic drugs that target these two genes.
Rosenberg et al. [49] demonstrated that the transfer of
lymphokine-activated killer (LAK) cells induced by
interleukin-2 (IL-2) could increase the survival rate of
patients with malignant tumors. In addition, mucosal
melanoma is a systemic disease that readily undergoes
DM; thus, LAK immunobiological therapy can help to
improve the prognosis of mucosal melanoma patients.
LAK cellular therapy is an emerging treatment modality
that has been applied to mucosal melanoma in recent
years [49, 50–52]. The core steps in this treatment are
the collection of venous blood, the in vitro incubation of
these blood samples with a certain concentration of IL-
2, and the subsequent transfusion of the blood back into
patients; patients are then treated with sustained admin-
istration of an appropriate concentration of IL-2 to
maintain LAK activity [52, 53]. Kanetaka et al. [54]
examined postoperative treatment with IL-2 and LAK in
13 HNMM patients and found that the 5-year DSS rates
of the group receiving the immunobiological treatment
and the untreated group were 67 and 33 %, respectively.
DM is regarded as an important cause of death among
HNMM patients. Although surgery, radiotherapy and
chemotherapy are the most common treatment ap-
proaches, they do not produce particularly strong
effects with respect to controlling DM. Thus, although
biological therapy for HNMM is uncommon, this type
of treatment approach nonetheless has potential
research value as an adjuvant therapy.
Moreover, in recent years, it has been confirmed that
immunobiological therapy produces certain radiation-
sensitizing effects on radiotherapy-resistant tumors.
The local tissue hypoxia caused by the strong metabolic
activity of tumor cells can induce local immunosuppres-
sive effects, which are manifested as tumor-promoting
disruptions in normal innate immunity [19]. Tissue
hypoxia can induce the local downregulation of the
interferon-γ (IFN-γ) immune response pathway and
thereby inhibit the activation of various mediating fac-
tors, such as CD4+/CD25+ regulatory factors (where
CD represents a cluster of differentiation), IL-10 and
transforming growth factor-b. A study has demonstrated
that the phenotype of activated IFN +CD8+ T cells was
associated with a 1.8-fold increase in tumor sensitivity
to radiotherapy [55]. Therefore, IFN-γ + CD8+ T cells
serve as a bridge between immune and radiotherapy re-
sponses, and can produce targeted radiosensitization ef-
fects. Clinically available immunological adjuvants and
tumor vaccines can become effective tools to simultan-
eously stimulate tumor immunosurveillance and enhance
radiotherapy responses. Although HNMM is highly malig-
nant, has a low incidence, and occurs through molecular
mechanisms that have not yet been fully elucidated, there
are nonetheless broad prospects for the potential use of
biological therapies in the treatment of this disease.
Study limitations
Potential bias in the included NRSs
Greater potential biases exist in NRSs than in RCTs [18]
Among these biases, selection bias is a major concern
because factors that influence prognosis occurred un-
evenly across different groups in the selected studies. In
addition, commonly observed imperfections in the NRSs
remain present in the reports, and in descriptions of
research protocols and the evaluations of measurements
that affect prognoses and results. These flaws all contrib-
ute to uncertainties in meta-analyses. In particular,
because a meta-analysis is a non-experimental observa-
tion study, completely uniform control standards could
not be achieved in the current meta-analysis; one spe-
cific manifestation of this issue is that uniform quality
control cannot be performed in each case. Therefore,
subgroup analysis (such as separate examinations of
different radiotherapy regimens, different clinical and
case stages, and cases involving lymphatic vascular inva-
sion) cannot be performed. These issues caused selection
bias in evaluations regarding the efficacy of postoperative
adjuvant radiotherapy, because in the included retrospect-
ive studies postoperative radiotherapy was mostly used in
patients with a positive safety margin, local metastasis,
DM and/or primary tumors with larger scopes.
Side effects of radiotherapy
HNMM lesions are located near various important tissues
and organs, such as the optic nerves and brain tissues.
Therefore, during the course of surgery and radiotherapy
patients may experience various adverse effects, including
optic nerve damage and mucositis, which will affect
prognosis. However, the relevant data of the included
publications were incomplete, and these publications
did not use uniform quality control standards; conse-
quently, the prognostic impact of radiotherapy-related
side effects on prognosis was not analyzed. However,
relevant reports have indicated that certain side effects
affect patient prognoses and survival times.
Radiotherapy subgroup analysis
In the present study the influence of radiotherapy on
prognosis, local control and metastasis was analyzed.
However, recent advances in radiotherapy techniques
and upgrades to radiotherapy equipment have led to the
development of novel radiotherapy strategies, such as
PT and CIT. In the context of HNMM, these novel strat-
egies are superior to conventional radiotherapy because
they can both control LR and improve patient survival.
In addition, compared with conventional radiotherapy,
these emerging radiotherapy approaches clearly produce
Li et al. BMC Cancer  (2015) 15:758 Page 14 of 16
reduced side effects. However, there are few relevant
reports regarding these approaches, the extant reports
involve small sample sizes, and studies of many potential
novel radiotherapy regimens remain in the experimental
stage. Therefore, future research will be required to
address this topic.
Conclusions
The current meta-analysis confirmed that the use of
postoperative radiotherapy can improve the local control
of HNMM but does not reduce the risk of death or
distant metastasis. However, with the development of
molecular mechanisms there are nonetheless broad
research prospects for the use of biological therapy and
radiotherapy in the treatment of this disease. Determin-
ation of the long-term effects of other adjuvant therapies
on patient prognosis will require additional examination
involving a large number of prospective clinical and
experimental studies.
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